Table 2. Comparison of haematological parameters with standard deviation between mild, moderate/severe and death groups, and survivor/non-survivor groups in COVID-19 patients.
| Parameter | Non-critical (Mild/Moderate) Group 1 (n = 59) | Critical-Survivors (Severe) Group 2 (n = 23) | Critical-Non-survivors (Death) Group 3 (n = 15) | P value |
|---|---|---|---|---|
| Age(years) | 49.2 ± 15.1 | 58.6 ± 16.4 * | 69.2 ± 10.6*,& | <0.001 |
| Gender (F/M) | 22/37 | 9/14 | 3/12 | |
| RBC (x106/uL) | 4.49 ± 0.64 | 3.97 ± 0.71 * | 3.67 ± 0.65* | 0.008 |
| Hgb (gr/dL) | 12.7 ± 1.8 | 11.34 ± 2.04* | 10.88 ± 1.99* | 0.018 |
| Hct (%) | 37.94 ± 4.8 | 34.4 ± 5.79* | 32.89 ± 6.01* | 0.004 |
| MCV (fL) | 84.97 ± 5.46 | 86.81 ± 3.7 | 89.61 ± 4.34* | 0.008 |
| MCH (pg) | 28.41 ± 1.97 | 28.55 ± 1.18 | 29.65 ± 1.53 | 0.124 |
| MCHC (g/dl) | 33.43 ± 1.19 | 32.91 ± 1.12 | 33.12 ± 1.41 | 0.085 |
| RDW-CV (%) | 13.29 ± 1.28 | 14.29 ± 1.35* | 15.01 ± 1.9* | 0.007 |
| WBC (ˣ103/L) | 7.3 ± 4.51 | 10.92 ± 5.69* | 10.84 ± 8.31* | 0.005 |
| NEUT (%) | 65.56 ± 15.09 | 76.24 ± 12.38* | 85.55 ± 7.92*,& | 0.002 |
| LYMPH (%) | 23.6 (13.1–32.3) | 12.65 (7.3–19.5)* | 7.6 (5.25–11.55) *,& | 0.001 |
| MONO (%) | 8.5(6.9–10.6) | 7.0 (4.95–9.22)* | 5.0 (3.45–7.15) * | 0.001 |
| EO (%) | 0.8 (0.20–2.10) | 0.5 (0.10–1.65) | 0.2 (0.0–1.10) * | 0.015 |
| BASO (%) | 0.3 (0.2–0.5) | 0.3 (0.1–0.4) | 0.2 (0.1–0.4) | 0.085 |
| PLT (x103/μL) | 241 ± 75 | 219 ± 84 | 90 ± 70 *,& | 0.001 |
| PDW (fL) | 11.69 ± 1.89 | 14.29 ± 1.35* | 15.01 ± 1.9* | 0.011 |
| MPV(fL) | 10.26 ± 0.89 | 10.42 ± 1.36 | 13.37 ± 2.74* | 0.014 |
| P-LCR (%) | 26.97 ± 7.08 | 28.08 ± 10.74 | 32.55 ± 8.23* | 0.006 |
| PCT (%) | 0.27 ± 0.11 | 0.33 ± 0.15 | 0.17 ± 0.1*,& | 0.002 |
| AS-LYMPH (%) | 0 (0–0.5) | 0 (0.0.47) | 0 (0–0.5) | 0.093 |
| RE-LYMPH (%) | 1.9 (1.0–2.7) | 1.2 (0.6–2.0)* | 0.9 (0.5–1.3) *,& | 0.003 |
| NEUT-RI | 49.64 ± 3.88 | 50.93 ± 3.98 | 53.77 ± 7.89* | 0.014 |
| NEUT-GI | 151.24 ± 5.4 | 151.7 ± 5.08 | 150.78 ± 4.97 | 0.459 |
| IG (%) | 0.5 (0.3–1.1) | 1.4 (0.8–2.9)* | 0.9 (0.8–1.6) *,& | 0.005 |
| NRBC (%) | 0 (0–0) | 0 (0–0.1) | 1 (0–0.1) * | 0.021 |
| NLR | 2.67 (1.8–5.1) | 6.2(3.2–11.3)* | 11.4 (6.9–16.8) *,& | <0.001 |
| MNR | 0.139 (0.09–0.189) | 0.092 (0.059–0.136)* | 0.060 (0.038–0.087) *,& | <0.001 |
Abbreviations: F:Female, M:Male, RBC: Red Blood Cell Count, Hgb: Hemoglobin, Hct(%): Haematocrit, MCV: Mean Cell Volume, MCH: Mean Cell Hemoglobin, MCHC: Mean Cell Hemoglobin Concentration, RDW-CV: Red Blood Cell Distribution Width-CV, WBC(%): % of White Blood Cells, NEUT(%): % of Neutrophils, LYMPH (%): % of Lymphocytes, MONO(%): % of Monocytes, EO(%): % of Eosinophils, BASO(%): % of basophils, PLT: Platelet Count, MPV: Mean Platelet Volume, PDW: Platelet distribution width, P-LCR: Platelet-Large Cell Ratio, PCT(%): Plateletcrit, AS-LYMPH(%):percentage of antibody synthesising lymphocyte, RE-LYMPH(%): Percentage of reactive lymphocyte, NEUT-RI: Neutrophil reactivity index, NEUT-GI: Neutrophil granularity index, IG(%): % of immature granulocytes, NRBC(%): % of nucleated red blood cells, NLR: Neutrophil lymphocyte ratio, MNR: Monocyte neutrophil ratio,
*,&: compared to critical survivors, critical non-survivors.